Moshkevich Solomon 4

What Happened
Solomon Moshkevich, President, Clinical Diagnostics at Natera (NTRA), sold a total of 4,639 shares in multiple open-market transactions on February 2–3, 2026, for aggregate proceeds of approximately $1,072,539. Individual reported transactions: 80 shares @ $228.50 ($18,280); 878 @ $229.96 ($201,903); 576 @ $230.84 ($132,964); 850 @ $232.33 ($197,477); 600 @ $233.24 ($139,942); 16 @ $234.00 ($3,744); and 1,639 @ $230.77 ($378,229). These were sales (not purchases).

Key Details

• Transaction dates: Feb 2–3, 2026. Report filed Feb 4, 2026 (timely within standard 2‑business‑day window).
• Total shares sold: 4,639; total proceeds reported: ~$1,072,539.
• Reported prices include weighted averages and multiple execution prices; footnotes show sale prices ranged roughly $229.57–$233.82 across lots.
• Footnotes: some sales were executed under a Rule 10b5‑1 trading plan adopted Nov 26, 2024; one sale was to satisfy tax withholding on RSU vesting per the Reporting Person’s Stock Unit Agreement (Jan 31, 2025).
• Shares owned after the transactions: not specified in the provided summary—see the Form 4 for post‑transaction holdings.

Context
Sales by executives can be routine (e.g., planned trading under a 10b5‑1 plan or tax withholding on vested awards) and do not by themselves indicate a company outlook. Here, the filing explicitly notes a 10b5‑1 plan and a tax‑withholding sale for RSUs, which point to planned or administrative reasons for the disposals rather than an ad‑hoc market timing decision.